Market Closed -
Nasdaq
21:00:00 10/05/2024 BST
5-day change
1st Jan Change
1.74
USD
-9.14%
-18.31%
-34.09%
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Growth Index
June 23, 2023 at 05:00 am
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Growth Index
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-09
CI
Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
04-08
North American Morning Briefing : Inflation Data, -2-
04-08
DJ
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-28
CI
North American Morning Briefing : Tech in Focus on -2-
03-25
DJ
North American Morning Briefing : Investors -2-
03-18
DJ
Jefferies Starts Cue Biopharma With Buy Rating
03-13
MT
Transcript : Cue Biopharma, Inc., Q3 2023 Earnings Call, Nov 09, 2023
11-09
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating
11-06
MT
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-03
CI
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb
11-03
MT
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023
11-03
CI
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?
26/09/23
CI
Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023
14/09/23
CI
Transcript : Cue Biopharma, Inc., Q2 2023 Earnings Call, Aug 09, 2023
09/08/23
Cue Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
08/08/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000 Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Growth Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell Small Cap Completeness Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Growth Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2500 Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000 Growth Index
23/06/23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Dynamic Index
23/06/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
More about the company
Last Close Price
1.74
USD
Average target price
9.4
USD
Spread / Average Target
+440.23%
Consensus
1st Jan change
Capi.
-34.09% 84.64M +3.91% 109B +10.87% 105B +0.23% 22.25B -13.14% 22.09B -7.68% 18.68B -38.36% 17.58B -10.66% 16.85B +3.75% 13.76B +36.70% 12.46B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1